Latest Strategy News

Hillgrove Resources has accelerated production at its Nugent centre ahead of schedule, driving an 8% rise in copper output and reducing costs. A $28 million capital raise will fund further development and exploration, underpinning growth prospects.

AdAlta Limited has completed the final share issuance under its Investment Agreement with the Meurs Group, securing the full $700,000 investment that bolstered its cellular immunotherapy development.

Liontown Resources delivered a robust September quarter with a significant ramp-up in underground mining at Kathleen Valley, alongside a fortified cash position and strategic contract amendments.

xReality Group Limited delivered a record-breaking first quarter in FY26, driven by a landmark $5.7 million contract with the Texas Department of Public Safety and a rapidly growing US customer base.

AdAlta Limited has made significant progress in its 'East to West' cellular immunotherapy strategy, advancing licensing negotiations for its first CAR-T product and raising $1.6 million through placements to bolster its financial position.

Peel Mining has secured $21.25 million through a placement and share purchase plan, while appointing a new leadership team to drive a strategic pivot focused on unlocking value from its copper and polymetallic assets in the Cobar Basin.

DUG Technology reports a robust start to FY26 with 19% revenue growth and a landmark SaaS and HPCaaS contract, marking key international milestones.

Sunshine Metals reports significant progress in North Queensland with standout gold intersections at Sybil and a $5 million placement led by Lion Selection. Board reshuffle aligns leadership with growth strategy.

CONNEQT Health has landed a significant Phase 2b clinical trial contract in the US, advancing its footprint in cardiovascular disease research with proprietary vascular assessment technology.

Tesoro Gold has reported a significant 42% increase in its Ternera gold resource alongside a robust scoping study and a $34 million equity raise to accelerate development of its El Zorro project in Chile.

Murray Cod Australia Ltd reports a robust start to FY26 with a 45% increase in sales and a $17 million capital raise, driven by expanded production and market access including new Halal certification.

Arovella Therapeutics has secured encouraging feedback from the US FDA on reagent testing for its CAR-iNKT cell therapy, setting the stage for an IND filing this quarter and clinical trials in early 2026.